default author photo

Antonio Giordano

Harvard University - Dana-Farber Cancer Institute

450 Brookline Avenue

Boston, MA 02115

United States

SCHOLARLY PAPERS

1

DOWNLOADS

147

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Efficacy and Safety of Systemic Therapies Following Progression on CDK4/6 Inhibitors in Patients with HR+/HER2-- Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis

Number of pages: 35 Posted: 13 Jun 2025
Scuola Superiore Meridionale, Vanvitelli University of Campania Luigi Vanvitelli, University of Naples Federico II, Baylor College of Medicine, University of Milan, University of Padova, University of Genova - Department of Internal Medicine and Medical Specialties (DiMI), Sapienza University of Rome, Baylor College of Medicine, Harvard University - Dana-Farber Cancer Institute, University of Naples Federico II, University of Naples Federico II, University of Naples Federico II, Fondazione IRCCS Istituto Nazionale dei Tumori, Gustave Roussy, Fondazione IRCCS Istituto Nazionale dei Tumori, Azienda USL Toscana Centro - Sandro Pitigliani Translational Research Unit, University of Udine - Deparment of Medicine (DAME), University of Naples Federico II, Vanvitelli University of Campania Luigi Vanvitelli, IRCCS-Fondazione Bietti and Baylor College of Medicine
Downloads 147 (505,974)

Abstract:

Loading...

HR+/HER2- metastatic breast cancer, CDK4/6 inhibitor resistance, Systematic Review, Network meta-analysis, Biomarker-driven therapy, Antibody-drug conjugates